WUHAN EASY DIAGNOSIS BIOMEDICINE CO.,LTD. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Stock
Equities
002932
CNE1000033Q7
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.02 CNY | -0.60% |
|
+0.60% | -12.84% |
| Sales 2021 | 2.83B 391M | Sales 2022 | 10.53B 1.45B | Capitalization | 8.95B 1.23B |
|---|---|---|---|---|---|
| Net income 2021 | 1.41B 195M | Net income 2022 | 4.21B 581M | EV / Sales 2021 | 2.09 x |
| Net cash position 2021 | 1.85B 255M | Net cash position 2022 | 4.3B 594M | EV / Sales 2022 | 0.44 x |
| P/E ratio 2021 |
4.99
x | P/E ratio 2022 |
2.1
x | Employees | 1,547 |
| Yield 2021 |
6.08% | Yield 2022 |
9.08% | Free-Float | 49.87% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.60% | ||
| 1 week | +0.60% | ||
| Current month | -8.08% | ||
| 1 month | -6.88% | ||
| 3 months | +2.93% | ||
| 6 months | -5.07% | ||
| Current year | -12.84% |
1 week
19.66
20.42
1 month
19.2522.33
Current year
14.8123.33
1 year
14.8137.13
3 years
14.8164.61
5 years
10.7164.61
10 years
7.9064.61
| Managers | Title | Age | Since |
|---|---|---|---|
Li Li Chen
CEO | Chief Executive Officer | 50 | 13-10-22 |
Guo Hui Zhou
DFI | Director of Finance/CFO | 40 | 21-08-17 |
Ying Wang
BRD | Director/Board Member | - | 13-10-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin Cheng Xie
BRD | Director/Board Member | 63 | 21-11-25 |
Xian Wang Shi
BRD | Director/Board Member | 56 | 22-10-20 |
Li Li Chen
CEO | Chief Executive Officer | 50 | 13-10-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 20.02 | -0.60% | 2 001 954 |
| 24-04-23 | 20.14 | +1.21% | 2,702,892 |
| 24-04-22 | 19.9 | -0.50% | 1,840,194 |
| 24-04-19 | 20 | +0.05% | 1,986,076 |
| 24-04-18 | 19.99 | -1.53% | 2,524,208 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
Calendar
2024-04-25
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -12.84% | 646M | |
| -11.57% | 7.4B | |
| +2.98% | 5.47B | |
| +0.98% | 4.51B | |
| +4.74% | 4.42B | |
| -51.04% | 3.29B | |
| +11.23% | 2.66B | |
| -16.38% | 2.07B | |
| -2.77% | 1.68B | |
| -10.84% | 1.66B |
- Stock Market
- Equities
- 002932 Stock
